Simple Summary Triple-negative breast cancer (TNBC) is the most aggressive breast cancer
subtype accounting for approximately 10–20% of all cases. Due to a lack of actionable …

The development of immunotherapy agents has revolutionized the field of oncology. The
only FDA-approved immunotherapeutic approach in breast cancer consists of immune …

Introduction Triple negative breast cancer (TNBC) is an area of high unmet medical need in
terms of new effective treatment strategies. Although breast cancer is traditionally …

Simple Summary For decades, countless efforts have been devoted to developing targeted
drugs to improve the prognosis of triple-negative breast cancer (TNBC). Among the novel …

Breast cancer is the most commonly diagnosed cancer (estimated 2.3 million new cases in
2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women …

Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of
breast cancer and has dismal prognosis. Local recurrence rate after standard therapy in the …

Introduction Triple-negative breast cancer (TNBC) is a breast cancer subtype characterized
by poorer prognosis. Despite that TNBC can display immunogenic features, anti-PD (L) 1 …

Triple negative breast cancer (TNBC) is a high-risk and aggressive malignancy
characterized by the absence of estrogen receptors (ER) and progesterone receptors (PR) …

Purpose Immunotherapy has started to transform the treatment of triple-negative breast
cancer (TNBC), in part due to the unique immunogenicity of this breast cancer subtype. This …

Triple-negative breast cancer (TNBC) is a clinically aggressive subtype of breast cancer that
represents 15–20% of breast tumors and is more prevalent in young pre-menopausal …